$EVFM company recently received an FDA approval for Non-Hormonal RX contraceptive gel called Phexxi. Administration an hour or less before Sexual activity. Launch is expected in Sept and company is working to have tx covered under the ACA so no cost for patient.

$EVFM Per company: roughly 885,000 patients based on 5% of target market. Company is estimating at around $1 Billion opportunity based on $200 cost per box. Contraceptive market in the United States roughly stands around $5.5 Billion.

$EVFM Gel Advantages:
1) No pill and no stress about if missed or skipped a dose
2) Risk of blood clots, cancer, mood alterations, weight gain, drug interactions, and smoking can inc risk of heart attack, stroke and blood clots with hormonal pill.
3) Use gel prior to activity.

$EVFM Raised $100 million cash at a secondary price of $3.5, roughly cash for 4-5 QTRS. Per company contraceptive effectiveness is as follows
Condoms 87%, Pills 93%, IUDs 99%, Phexxi 87%. Evofem states Phexxi 93.3% effective if used as directed.

$EVFM MC roughly below $300 million mark. Looking at the charts, MACD is positive and gap fill to 5 plus (200 SMA) at some point. Stock hit as high as 9 plus on approval and since than subsequent pullback to 2's. Added decent quantity around 2.8 and planning to hold long term.